Skip to content

BIOSPECIFICS TECHNOLOGIES CORP: 10-Q filed 2013-08-09

What BIOSPECIFICS TECHNOLOGIES CORP reported in its quarterly report filed 2013-08-09 (fiscal Q2 2013): 30 published measures, 86 facts as tagged in accession 0001140361-13-031299.

This filing

Form
10-Q (quarterly report)
Filed
2013-08-09
Fiscal period
fiscal Q2 2013
Accession
0001140361-13-031299 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSPECIFICS TECHNOLOGIES CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-06-3020,920,768USD
At 2012-12-3118,390,264USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-06-3019,548,213USD
At 2012-12-3117,458,346USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-06-304,017,531USD
At 2012-12-313,383,737USD
At 2012-06-303,788,173USD
At 2011-12-313,196,831USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,028,186USD91
2013-01-01 to 2013-06-302,381,270USD181
2012-04-01 to 2012-06-30666,682USD91
2012-01-01 to 2012-06-301,409,072USD182

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-06-303,877,609USD181
2012-01-01 to 2012-06-302,397,194USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-396,851USD181
2012-01-01 to 2012-06-30-305,852USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-2,846,964USD181
2012-01-01 to 2012-06-30-1,500,000USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2013-06-302,070,441USD
At 2012-12-31-310,829USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2013-04-01 to 2013-06-306,345,277shares91
2013-01-01 to 2013-06-306,351,083shares181
2012-04-01 to 2012-06-306,343,356shares91
2012-01-01 to 2012-06-306,339,930shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2013-04-01 to 2013-06-306,968,057shares91
2013-01-01 to 2013-06-306,966,045shares181
2012-04-01 to 2012-06-306,971,687shares91
2012-01-01 to 2012-06-306,984,258shares182

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2013-04-01 to 2013-06-300.16USD/shares91
2013-01-01 to 2013-06-300.37USD/shares181
2012-04-01 to 2012-06-300.11USD/shares91
2012-01-01 to 2012-06-300.22USD/shares182

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2013-04-01 to 2013-06-300.15USD/shares91
2013-01-01 to 2013-06-300.34USD/shares181
2012-04-01 to 2012-06-300.1USD/shares91
2012-01-01 to 2012-06-300.2USD/shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-04-01 to 2013-06-30542,009USD91
2013-01-01 to 2013-06-301,261,459USD181
2012-04-01 to 2012-06-30390,651USD91
2012-01-01 to 2012-06-30906,228USD182

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-06-30105,449USD181
2012-01-01 to 2012-06-30175,685USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,563,685USD91
2013-01-01 to 2013-06-303,630,353USD181
2012-04-01 to 2012-06-301,047,562USD91
2012-01-01 to 2012-06-302,296,036USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-06-3016,430,099USD
At 2012-12-3113,875,801USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-06-301,199,730USD
At 2012-12-31724,528USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2013-06-303,903,942USD
At 2012-12-315,082,360USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2013-01-01 to 2013-06-30396,851USD181
2012-01-01 to 2012-06-30485,904USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-04-01 to 2013-06-30470,044USD91
2013-01-01 to 2013-06-30764,918USD181
2012-04-01 to 2012-06-30404,346USD91
2012-01-01 to 2012-06-30653,898USD182

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-06-3020,794,154USD
At 2012-12-3120,688,706USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2013-06-30248,160USD
At 2012-12-31280,322USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-06-30411,110USD
At 2012-12-31149,724USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,570,195USD91
2013-01-01 to 2013-06-303,642,729USD181
2012-04-01 to 2012-06-301,057,333USD91
2012-01-01 to 2012-06-302,315,300USD182

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,028,186USD91
2013-01-01 to 2013-06-302,381,270USD181
2012-04-01 to 2012-06-30666,682USD91
2012-01-01 to 2012-06-301,409,072USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-04-01 to 2013-06-301,236,254USD91
2013-01-01 to 2013-06-302,854,736USD181
2012-04-01 to 2012-06-301,149,926USD91
2012-01-01 to 2012-06-302,238,648USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2013-01-01 to 2013-06-3032,162USD181
2012-01-01 to 2012-06-3029,019USD182

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-04-01 to 2013-06-3016,100USD91
2012-04-01 to 2012-06-3029,000USD91

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-04-01 to 2013-06-306,510USD91
2013-01-01 to 2013-06-3012,376USD181
2012-04-01 to 2012-06-309,771USD91
2012-01-01 to 2012-06-3019,264USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-06-30-1,178,418USD181
2012-01-01 to 2012-06-30-416,072USD182

Inspect the source

Entity
BIOSPECIFICS TECHNOLOGIES CORP / CIK 0000875622
Captured
SEC response SHA-256
b1d443fa8a2de5e07d7cbcf40e33944d546011c718a394f04bbb863281862def

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000875622.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))